ARAY240719C1000
- 0.69
- 0.000.00%
Accuray Newsroom
Accuray (ARAY) Gets a Buy From Lake Street
Accuray's Buy Rating Affirmed Despite Challenges, With Positive Long-Term Growth and Overseas Market Expansion
Accuray Analyst Ratings
Accuray (ARAY) Gets a Buy From Lake Street
BTIG Keeps Their Buy Rating on Accuray (ARAY)
Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), UnitedHealth (UNH) and Accuray (ARAY)
Accuray's Stock Potential: An In-depth Analysis of Its Buy Rating Based on Updated F24 Guidance
B. Riley Trims Accuray's Price Target to $6.50 From $7.50 on Lower Multiple, Maintains Buy Rating
Analysts' Top Healthcare Picks: Accuray (ARAY), Gritstone Oncology (GRTS)
TD Cowen Keeps Their Buy Rating on Accuray (ARAY)
Accuray (ARAY) Gets a Buy From Lake Street
Strong Financial Performance and Future Catalysts Bolster Buy Rating for Accuray: An Analysis by Marie Thibault
Accuray's Promising Growth Prospects: A Buy Recommendation Based on Revenue Strategies, Market Expansion, and Strategic Partnerships
B. Riley Securities Reiterates Buy on Accuray, Maintains $7.5 Price Target
Accuray Analyst Ratings
Accuray (ARAY) Positioned for Growth: Buy Rating Supported by Chinese Market Expansion, New Product Launches, and Strong Financial Projections
Accuray's Market Potential in China and Advancements in Adaptive Therapy Bolster Buy Rating
Lake Street Keeps Their Buy Rating on Accuray (ARAY)
B.Riley Financial Reaffirms Their Buy Rating on Accuray (ARAY)
B.Riley Financial Remains a Buy on Accuray (ARAY)